GLP-1 agonists induce weight loss and alleviate headache in idiopathic intracranial hypertension Presented ByDr Nik Krajnc, Medical University of Vienna, Austria ConferenceEAN 2023 7 September, 2023 11:00
80% of patients reverse from chronic to episodic migraine on anti-CGRP antibodies Presented ByDr Gabriella Egeo, IRCCS San Raffaele, Italy ConferenceEAN 2023 7 September, 2023 10:52
Lecture on migraine: from the prodromal phase to future paradigm shifts Presented ByProf. Peter Goadsby, King's College London, UK ConferenceAAN 2023 26 June, 2023 20:24
Zavegepant nasal spray exhibits good efficacy and safety in acute migraine Presented ByProf. Richard Lipton, Albert Einstein College of Medicine, NY, USA TrialPhase 3 ConferenceAAN 2023 26 June, 2023 20:18
Atogepant helps prevent treatment-resistant episodic migraine TrialELEVATE ConferenceAAN 2023 26 June, 2023 20:13
Simultaneous head-to-head comparison of 25 migraine medications ConferenceAAN 2023 26 June, 2023 20:10
A vaccine as a potentially safe and effective immunotherapy against CGRP Presented ByDr Jean-Cosme Dodart, Vaxxinity Inc, FL, USA TrialPhase 1, UB-313 ConferenceAAN 2023 26 June, 2023 20:04
Patients with migraines smoke less, drink less, and use fewer illicit drugs than general population Presented ByDr Thomas van den Hoek, Leiden University Medical Center, the Netherlands ConferenceEHC 2022 5 January, 2023 11:43
Large gaps worldwide in prophylactic treatment of migraine TrialCaMEO-I ConferenceEHC 2022 5 January, 2023 11:40
Atogepant for the preventive treatment of chronic migraine TrialPhase 3, PROGRESS ConferenceEHC 2022 5 January, 2023 11:36
EHF consensus on effective migraine treatment and triptan failure Presented ByProf. Uwe Reuter, Charité University Hospital of Berlin, Germany ConferenceEHC 2022 5 January, 2023 11:31
Sustained long-term effect of occipital nerve stimulation in MICCH Presented ByDr Roemer Brandt, Leiden University Medical Centre, Netherlands TrialICON ConferenceEHC 2022 5 January, 2023 11:28
Onabotulinumtoxin A effective in older patients with chronic migraine Presented ByDr Raffaele Ornello , University of L’Aquila, Italy ConferenceEHC 2022 5 January, 2023 11:23
Zavegepant nasal spray effective for the acute treatment of migraine Presented ByDr Robert Croop TrialPhase 3 ConferenceEHC 2022 5 January, 2023 11:15
What to do when conventional treatment of headache fails in children Presented ByProf. Ishaq Abu-Arafeh, Royal Hospital for Children, Glasgow, UK ConferenceEHC 2022 5 January, 2023 11:12
IHS President: “It is time for operationalisation of ICHD” Presented ByProf. Cristina Tassorelli , University of Pavia, Italy ConferenceEHC 2022 5 January, 2023 10:57
Persistent headache after stroke: not rare and often overlooked Presented ByProf. Elena Lebedeva, Ural State Medical University, Russia ConferenceEHC 2022 5 January, 2023 10:25
Additional effects of gepants on top of erenumab Presented ByDr Tessa de Vries, Erasmus Medical Center, the Netherlands ConferenceEHC 2022 5 January, 2023 10:05
Targeting cortical activation by transcranial magnetic stimulation Presented ByDr Anna Andreou, King's College London, United Kingdom ConferenceEAN 2022 22 August, 2022 15:07
Erenumab more than doubles plasma CGRP levels Presented ByDr Nina Vashchenko, Sechenov First Moscow State Medical University, Russia ConferenceEAN 2022 22 August, 2022 15:03
Over a third of patients responds late to CGRP antibodies Presented ByDr Cinzia Aurilia, University of Florence, Italy ConferenceEAN 2022 22 August, 2022 14:59
Zavegepant nasal spray provides ultra-rapid relief of acute migraine ConferenceAmerican Headache Society annual meeting 17 June, 2022 15:45
Migraine may be an important obstetric risk factor Presented ByDr Alexandra Purdue-Smithe, Harvard Medical School, MA, USA ConferenceAAN 2022 2 June, 2022 14:57
Intranasal zavegepant safe and well tolerated in healthy adults Presented ByProf. Richard Bertz, University of Pittsburgh, PA, USA ConferenceAAN 2022 2 June, 2022 14:52
Telemedicine during COVID-19 pandemic highly appreciated Presented ByDr Chia-Chun Chiang, Mayo Clinic, MN, USA ConferenceAAN 2022 2 June, 2022 14:38
CGRP inhibitor erenumab safe and effective in migraine with aura JournalJAMA Neurology 22 December, 2021 17:04
Brain Prize Lecture: Prof. Jes Olesen on migraine Presented ByProf. Jes Olesen, University of Copenhagen, Denmark ConferenceECNP 2021 26 November, 2021 11:02
Occipital nerve stimulation effective and safe in chronic cluster headache Presented ByDr Poldi Wilbrink, Zuyderland Medical Centre, the Netherlands TrialPhase 3, ICON ConferenceIHC 2021 8 November, 2021 16:30
Insights in drug-drug interactions facilitate rational polypharmacy Presented ByDr Victor Kaytser, Robert Wood Johnson Medical School, TX, USA ConferenceIHC 2021 8 November, 2021 16:26
Rimegepant confers long-term improvements in MMDs Presented ByEvan Popoff, Broadstreet Health Economics & Outcomes Research, Canada TrialPhase 2, BHV3000-201 ConferenceIHC 2021 8 November, 2021 16:19
First real-world effectiveness data of erenumab is promising Presented ByProf. Andreas R. Gantenbein, Zurzach Care, Switzerland TrialSQUARE ConferenceIHC 2021 8 November, 2021 16:11
Galcanezumab effective in patients with episodic or chronic cluster headache Presented ByDr Charly Gaul, Headache Clinic Königstein, Germany TrialPhase 3 ConferenceIHC 2021 8 November, 2021 16:04
Central effects and affected somatosensory processing with galcanezumab in migraine Presented ByDr Hauke Basedau, Dr Kuan-Po Peng, University Medical Centre Hamburg-Eppendorf, Germany ConferenceIHC 2021 8 November, 2021 16:00
Long-term safety and tolerability of atogepant in migraine Presented ByProf. Laszlo Mechtler, DENT Neurologic Institute, NY, USA TrialPhase 3, ADVANCE trial ConferenceIHC 2021 8 November, 2021 15:53
Largest genome-wide association study of migraine to date Presented ByHeidi M. Hautakangas, Institute for Molecular Medicine, Finland ConferenceIHC 2021 8 November, 2021 15:39
Robust evidence that cluster headache has a genetic basis Presented ByDr Bendik S. Winsvold, Oslo University Hospital, Norway ConferenceIHC 2021 8 November, 2021 15:35
Functional brainstem somatotopy of the trigeminal nerve during nociception Presented ByDr Lisa-Marie Sturm, University Clinic Hamburg Eppendorf, Germany ConferenceIHC 2021 8 November, 2021 15:25
Morphological changes in cluster headache between attacks Presented ByDr Kuan-Lin Lai, Taipei Veterans General Hospital, Taiwan ConferenceIHC 2021 8 November, 2021 15:21
Interictal pontine metabolism in migraine patients without aura Presented ByDr Samaira Younis, Danish Headache Centre, Denmark ConferenceIHC 2021 8 November, 2021 14:55
AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine Presented ByDr Nikita Chhabra, Mayo Clinic, NY, USA ConferenceIHC 2021 8 November, 2021 14:45
Migraine may not be a risk factor for stroke Presented ByCevdet Acarsoy, Erasmus Medical Centre, the Netherlands TrialThe Rotterdam study ConferenceIHC 2021 8 November, 2021 14:38
Predictors of health-related quality of life in cluster headache Presented ByDr Soo-Kyoung Kim, Gyeongsang National University, South Korea ConferenceIHC 2021 8 November, 2021 14:29
Dry eye disease is more prevalent in migraine Presented ByDr Bithi Chowdhury, Hindu Rao Hospital and MDMC Medical College, India ConferenceIHC 2021 8 November, 2021 14:25
Voice change and throat swelling are cranial autonomic symptoms in primary headache Presented ByDr Nazia Karsan, King’s College London, UK ConferenceIHC 2021 8 November, 2021 14:20
Association between physical inactivity and headache disorders Presented ByDr Arão Oliveira, University of São Paulo, Brazil TrialELSA-Brasil cohort ConferenceIHC 2021 8 November, 2021 14:13
Increased suicidal attempts and risks of ideation in medication-overuse headache Presented ByDr Yen-Feng Wang, Taipei Veterans General Hospital, Taiwan ConferenceIHC 2021 8 November, 2021 14:08
Telemedicine beneficial for headache care during the pandemic Presented ByDr Chia-Chun Chiang , Mayo Clinic, NY, USA ConferenceIHC 2021 8 November, 2021 13:58
Comparison of headaches after SARS-CoV-2 vaccination Presented ByDr Carl Göbel, Universitätsklinikum Schleswig-Holstein, Germany ConferenceIHC 2021 8 November, 2021 13:55
Grey matter cortical changes in patients with persistent headache after COVID-19 Presented ByDr Álvaro Planchuelo-Gómez, Universidad de Valladolid, Spain ConferenceIHC 2021 8 November, 2021 13:43
Increased risk of cerebral venous thrombosis in COVID-19 Presented ByDr Sajid Hameed , Aga Khan University, Pakistan ConferenceIHC 2021 8 November, 2021 13:26
IHC 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceIHC 2021 30 September, 2021 23:06
Oral atogepant therapy trims number of days with migraines, headaches JournalThe New England Journal of Medicine 18 August, 2021 23:00
Factors associated with decreased migraine attack risk Presented ByProf. Christian Wöber, Medical University of Vienna, Austria ConferenceEAN 2021 18 August, 2021 10:59
Eptinezumab shows acute benefits during migraine attack TrialPhase 3, RELIEF ConferenceEAN 2021 18 August, 2021 10:58
Erenumab superior to topiramate for migraine treatment TrialPhase 4, HER-MES ConferenceEAN 2021 18 August, 2021 10:57
Pregnant migraine patients at higher risk of complications Presented ByDr Nirit Lev, Rabin Medical Center, Israel ConferenceEAN 2021 18 August, 2021 10:53
Occipital nerve stimulation in drug-resistant cluster headache Presented ByDr Javier Membrilla, University Hospital La Paz, Spain ConferenceEAN 2021 18 August, 2021 10:51
Rhythmicity in primary headache disorders Presented ByDr Christoph Schankin, University Hospital of Bern, Switzerland ConferenceEAN 2021 18 August, 2021 10:50
Virtual roller coaster tied to dizziness, motion sickness in migraine patients JournalNeurology 22 July, 2021 19:29
Diet rich in omega-3 fatty acids may help quiet persistent migraines JournalThe BMJ 1 July, 2021 23:32
Migraine not just a neurological problem for pregnant women Conference7th Congress of the European Academy of Neurology 22 June, 2021 18:19
Long-term safety of atogepant as migraine prophylaxis Presented ByProf. Messoud Ashina, University of Copenhagen, Denmark ConferenceAAN 2021 16 June, 2021 11:51
Intranasal zavegepant effective treatment for acute migraine TrialPhase 3 ConferenceAAN 2021 16 June, 2021 11:50
Ubrogepant for acute treatment of perimenstrual migraine TrialPhase 3 ConferenceAAN 2021 16 June, 2021 11:50
CGRP antagonists and complications in patients with Raynaud’s phenomenon ConferenceAAN 2021 16 June, 2021 11:49
Efficacy and safety of eptinezumab in acute migraine TrialPhase 3, RELIEF ConferenceAAN 2021 16 June, 2021 11:41
CGRP monoclonal antibodies blurring the line between migraine prevention and treatment JournalJAMA 15 June, 2021 18:38
Headache disorders may up risk for temporomandibular disorders ConferenceAmerican Headache Society annual meeting 11 June, 2021 16:04
Zavegepant nasal spray promises ultra-rapid relief from acute migraine ConferenceAmerican Headache Society annual meeting 10 June, 2021 16:03
Mindfulness-based stress reduction tied to less disability, depression with migraine JournalJAMA Internal Medicine 14 December, 2020 23:11
Later school start time linked to fewer migraines in adolescents JournalHeadache: The Journal of Head and Face Pain 7 December, 2020 20:11
Prednisone can help prevent episodic cluster headache JournalThe Lancet Neurology 3 December, 2020 18:05
Improvement of migraine using CGRP mAbs in a real-world setting Presented ByProf. Robert E. Shapiro, University of Vermont, VT, USA TrialOVERCOME ConferenceMTIS 2020 27 October, 2020 15:47
Similar treatment needs for high-frequency episodic and low-frequency chronic migraine Presented ByProf. Richard B. Lipton, Albert Einstein College of Medicine, NY, USA TrialCaMEO ConferenceMTIS 2020 27 October, 2020 15:44
Nitroglycerin-induced cluster headache attacks characterised comprehensively Presented ByDr Diana Y. Wei, King's College London, UK ConferenceMTIS 2020 27 October, 2020 15:40
Remote electrical neuromodulation useful for adolescents with migraine Presented ByDr Andrew D. Hershey, Cincinnati Children's Hospital Medical Center, USA ConferenceMTIS 2020 27 October, 2020 15:38
Concomitant preventive medication has no impact on efficacy of ubrogepant Presented ByDr Andrew M. Blumenfeld, Headache Center of Southern California, USA TrialPhase 3, ACHIEVE I and II ConferenceMTIS 2020 27 October, 2020 15:36
No new cardiovascular safety concerns with long-term use of lasmiditan Presented ByDr H. Hochstetler TrialPhase 3, GLADIATOR ConferenceMTIS 2020 27 October, 2020 15:19
Less medication use and fewer doctor visits with galcanezumab in treatment-resistant migraine Presented ByProf. Julio P. Gómez, Hospital Universitario Marqués de Valdecilla, Spain TrialPhase 3, CONQUER ConferenceMTIS 2020 27 October, 2020 15:16
Real-world evidence reveals physicians’ perception of erenumab Presented ByDr Mirja Koch, Clinical Research Neuroscience, Novartis Pharma GmbH, Germany TrialTELESCOPE ConferenceMTIS 2020 27 October, 2020 15:14
Early initiation of lasmiditan improves migraine outcomes Presented ByDr Mario F. Peres, Hospital Israelita Albert Einstein, Brazil TrialPhase 3, GLADIATOR ConferenceMTIS 2020 27 October, 2020 15:11
Fremanezumab effective in patients with migraine and comorbid depression Presented ByProf. Dawn C. Buse, Albert Einstein College of Medicine, NY, USA TrialPhase 3, FOCUS, HALO ConferenceMTIS 2020 27 October, 2020 15:08
Long-term onabotulinumtoxinA improves quality of life in migraine Presented ByDr Guy Boudreau, Centre Hospitalier Universitaire de Montréal, Canada TrialPREDICT ConferenceMTIS 2020 27 October, 2020 15:04
Sustained shift in migraine status using galcanezumab Presented ByDr William S. Kingston, Sunnybrook Health Sciences Centre, Canada TrialPhase 3, CONQUER ConferenceMTIS 2020 27 October, 2020 14:35
Worldwide survey shows substantial burden of migraine Presented ByDr D.D. Mitsikostas ConferenceMTIS 2020 27 October, 2020 14:33
Long-term efficacy and safety of fremanezumab in treatment-resistant migraine Presented ByDr M. Ashina TrialPhase 3, FOCUS ConferenceMTIS 2020 27 October, 2020 14:31
Injection-site reactions with galcanezumab are mild and self-limiting Presented ByDr V.L. Stauffer TrialPhase 3, CONQUER ConferenceMTIS 2020 27 October, 2020 14:27
Migraine as a cyclical functional disorder Presented ByMr Daniele Martinelli, University of Pavia, Italy ConferenceEAN 2020 10 September, 2020 11:07
Reassuring real-world safety profile of 3 CGRP inhibitors Presented ByProf. Stephen D. Silberstein, Thomas Jefferson University, PA, USA ConferenceEAN 2020 10 September, 2020 11:03
Long-term cardiovascular safety of erenumab Presented ByDr Stewart Tepper, Geisel School of Medicine, USA ConferenceEAN 2020 10 September, 2020 10:58
Real-world data for erenumab in Germany Presented ByProf. Andreas Straube, Ludwig-Maximilians-University Munich, Germany TrialTELESCOPE ConferenceEAN 2020 9 September, 2020 17:13
Eptinezumab in chronic migraine and medication-overuse headache Presented ByProf. Hans-Christoph Diener, Medical Faculty of the University Duisburg-Essen, Germany TrialPhase 3, PROMISE-2 ConferenceEAN 2020 9 September, 2020 17:09
Fremanezumab tolerability in cardiovascular patients with migraine Presented ByDr Gianluca Coppola, Sapienza University of Rome, Italy TrialPhase 3, HALO, FOCUS ConferenceEAN 2020 9 September, 2020 17:05
Effects of galcanezumab on health-related quality of life Presented ByDr Stewart Tepper, Geisel School of Medicine, USA TrialPhase 3, CONQUER ConferenceEAN 2020 9 September, 2020 16:44
Unmet needs and pipeline Presented ByProf. Christian Lampl, Headache Medical Center, Austria ConferenceEAN 2020 9 September, 2020 16:39
The role of neurogenic inflammation in migraine Presented ByProf. Lars Edvinsson, Lund University, Sweden ConferenceEAN 2019 27 August, 2019 23:09
Atogepant efficacious, safe, and well-tolerated for migraine prevention ConferenceEAN 2019 27 August, 2019 22:11
Galcanezumab reduces healthcare resource utilisation TrialPhase 3, REGAIN ConferenceEAN 2019 27 August, 2019 19:17
Lasmiditan in migraine patients with CV risk factors TrialPhase 3, SAMURAI and SPARTAN ConferenceEAN 2019 27 August, 2019 18:18
Factors influencing choice of prophylactic migraine therapy TrialPANORAMA ConferenceEAN 2019 27 August, 2019 15:19
Long-term efficacy and safety of erenumab TrialPhase 3, STRIVE ConferenceAAN 2019 30 July, 2019 22:34
Eptinezumab reduces mean monthly migraine days TrialPhase 3, PROMISE ConferenceAAN 2019 30 July, 2019 21:35
Lasmiditan: rapid onset of efficacy in acute migraine TrialPhase 3, SPARTAN, SAMURAI ConferenceAAN 2019 30 July, 2019 19:37
Efficacy, tolerability, and safety of ubrogepant confirmed TrialPhase 3, ACHIEVE ConferenceAAN 2019 30 July, 2019 17:39
Galcanezumab reduces cluster headache frequency ExpertDr David Dodick, Mayo Clinic, Phoenix, USA ConferenceAAN 2019 30 July, 2019 16:40
Lessons learned from triptan therapy Presented ByDr Patricia Pozo-Rosich & Prof. Rami Burstein TrialPREEMPT ConferenceTOXINS 2019 15 March, 2019 23:51
Central and peripheral mechanisms in migraine Presented ByProf. Anthony Dickenson, University College London, United Kingdom ConferenceTOXINS 2019 15 March, 2019 22:54